Chimeric Antigen Receptor T-Cell
Chimeric Antigen Receptor T-Cell (CAR-T) Therapy
In 2017, the FDA approved the first ever gene immunotherapy to treat cancer. It is called chimeric antigen receptor T-cell therapy or CAR-T, for short. The one-time treatment is now being used to treat some adults and children with certain types of blood cancers.
¿Quieres leer esto en español? Haga clic aquí.
Chimeric antigen receptor T-cell therapy or CAR-T is a personalized cancer therapy that teaches the immune system’s T cells to target cancer cells
There is currently no CAR-T immunotherapy approved to treat breast cancer. But researchers are investigating whether CAR-T and other types of gene therapies might be effective in treating solid tumors, like breast cancer, and a few clinical trials have already gotten underway. The clinical trials currently studying CAR-T in breast cancer can be found here on BreastCancerTrials.org You can learn more about how a cancer patient’s T cells are engineered in a lab to fight cancer cells in this section of the National Cancer Institute’s website.
And you can learn more about immunotherapy in general in this section of our website.